Total Long Term Debt (Quarterly) Chart

View Total Long Term Debt (Quarterly) for SUPN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Total Long Term Debt (Quarterly) Chart
Start Trial

Historical Total Long Term Debt (Quarterly) Data

View and export this data back to 2012. Start Trial.
Date Value
June 30, 2026 29.43M
March 31, 2026 30.27M
December 31, 2025 30.36M
September 30, 2025 31.42M
June 30, 2025 24.38M
March 31, 2025 26.37M
December 31, 2024 27.38M
September 30, 2024 28.93M
June 30, 2024 30.29M
March 31, 2024 32.99M
December 31, 2023 33.20M
September 30, 2023 33.84M
June 30, 2023 34.18M
March 31, 2023 36.51M
December 31, 2022 36.00M
September 30, 2022 36.03M
June 30, 2022 38.44M
March 31, 2022 444.06M
December 31, 2021 420.55M
September 30, 2021 420.19M
June 30, 2021 416.55M
March 31, 2021 429.51M
December 31, 2020 427.74M
September 30, 2020 429.80M
June 30, 2020 427.02M
Date Value
March 31, 2020 402.06M
December 31, 2019 398.10M
September 30, 2019 391.68M
June 30, 2019 388.51M
March 31, 2019 385.52M
December 31, 2018 354.22M
September 30, 2018 350.86M
June 30, 2018 347.45M
March 31, 2018 344.03M
December 31, 2017 26.54M
September 30, 2017 27.96M
June 30, 2017 30.65M
March 31, 2017 33.51M
December 31, 2016 34.56M
September 30, 2016 5.772M
June 30, 2016 5.699M
March 31, 2016 5.627M
December 31, 2015 37.61M
September 30, 2015 8.068M
June 30, 2015 8.608M
March 31, 2015 11.48M
December 31, 2014 26.95M
September 30, 2014 26.50M
June 30, 2014 28.67M
March 31, 2014 28.36M

Total Long Term Debt Definition

Represents a company's total debt maturing for more than 12 months of the reporting period.

Read full definition.

Total Long Term Debt (Quarterly) Range, Past 5 Years

View Total Long Term Debt (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Total Long Term Debt (Quarterly) Benchmarks

View Total Long Term Debt (Quarterly) Benchmarks
Start Trial
Indivior Pharmaceuticals, Inc. 500.00M
Pfizer Inc. 63.10B
Amphastar Pharmaceuticals, Inc. 679.52M
Collegium Pharmaceutical, Inc. 1.216B
Bristol Myers Squibb Co. 44.59B